Samsrita Labs
BSE: SAMSRITA · Healthcare Service Provider
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Samsrita Labs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Samsrita Labs Limited is an Indian healthcare and life sciences company that provides diagnostic testing services, medical research, and pharmaceutical distribution. The firm focuses on integrating advanced biotechnology, including regenerative medicine and stem cell research, with traditional clinical diagnostic delivery.
Business Model
The company generates revenue by operating a network of diagnostic centres and specialised laboratory facilities that cater to clinical testing demands. It further leverages its research capabilities in biotechnology to provide specialised medical services.
Management Commentary
Management aims to expand the company's footprint in the domestic medical services market by scaling its diagnostic infrastructure and advancing its biotechnology research initiatives.
Growth Outlook
Growth is expected to be driven by the increasing demand for clinical testing in India and the integration of regenerative medicine into the company's service portfolio.
Key Risks
- Regulatory Compliance. The company is subject to stringent healthcare and biotechnology regulations that may impact operational costs and service delivery.
- Market Competition. The diagnostic and life sciences sector in India is highly competitive, potentially pressuring margins and market share.
- Technological Obsolescence. Rapid advancements in medical technology require continuous capital investment to remain relevant in the diagnostic and research space.
- Liquidity Risk. As a small-cap entity, the company may face challenges regarding capital access and stock liquidity compared to larger industry peers.
Start your research today
Unlock AI insights, financials, peers and live data on Samsrita Labs and 5,000+ companies — free.
Key Metrics
NET PROFIT
₹9 Cr
TTM · standalone
EPS
₹3.90
TTM · standalone
RETURN ON EQUITY
73.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
72.4%
TTM · standalone
P/E
3.4x
Q4 FY26 · standalone
EV/EBITDA
4.1x
Q4 FY26 · standalone
Peers · Healthcare Service Provider
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Samsrita LabsSAMSRITA | ₹25 Cr | 2.83 | 2.90 | — | 43450.0% | 73.1% | 72.4% | -43.6% |
Krsnaa Diagnostics Ltd.KRSNAA | ₹1,830 Cr | 18.76 | 8.80 | 10.2% | 32.5% | 10.5% | 13.3% | -28.5% |
Suraksha Diagnostic Ltd.SURAKSHA | ₹1,772 Cr | 48.60 | 16.73 | 22.5% | 32.7% | 15.8% | 18.6% | +14.0% |
3B BlackBio Dx Ltd3BBLACKBIO | ₹1,237 Cr | 20.61 | 14.59 | 41.9% | 58.0% | 21.2% | 26.3% | +0.5% |
One Global Service Provider LimitedONEGLOBAL | ₹1,068 Cr | — | — | — | 19.0% | — | — | +114.9% |
Gaudium IVF and Women Health LimitedGAUDIUMIVF | ₹886 Cr | — | — | — | 36.0% | — | — | — |
As of Q4 FY26
Financials
Samsrita Labs
BSE: SAMSRITA · Healthcare Service Provider
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Samsrita Labs's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Samsrita Labs Limited is an Indian healthcare and life sciences company that provides diagnostic testing services, medical research, and pharmaceutical distribution. The firm focuses on integrating advanced biotechnology, including regenerative medicine and stem cell research, with traditional clinical diagnostic delivery.
Business Model
The company generates revenue by operating a network of diagnostic centres and specialised laboratory facilities that cater to clinical testing demands. It further leverages its research capabilities in biotechnology to provide specialised medical services.
Management Commentary
Management aims to expand the company's footprint in the domestic medical services market by scaling its diagnostic infrastructure and advancing its biotechnology research initiatives.
Growth Outlook
Growth is expected to be driven by the increasing demand for clinical testing in India and the integration of regenerative medicine into the company's service portfolio.
Key Risks
- Regulatory Compliance. The company is subject to stringent healthcare and biotechnology regulations that may impact operational costs and service delivery.
- Market Competition. The diagnostic and life sciences sector in India is highly competitive, potentially pressuring margins and market share.
- Technological Obsolescence. Rapid advancements in medical technology require continuous capital investment to remain relevant in the diagnostic and research space.
- Liquidity Risk. As a small-cap entity, the company may face challenges regarding capital access and stock liquidity compared to larger industry peers.
Start your research today
Unlock AI insights, financials, peers and live data on Samsrita Labs and 5,000+ companies — free.
Key Metrics
NET PROFIT
₹9 Cr
TTM · standalone
EPS
₹3.90
TTM · standalone
RETURN ON EQUITY
73.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
72.4%
TTM · standalone
P/E
3.4x
Q4 FY26 · standalone
EV/EBITDA
4.1x
Q4 FY26 · standalone
Peers · Healthcare Service Provider
As of Q4 FY26